Provided by Tiger Trade Technology Pte. Ltd.

XOMA Corp

30.17
-0.3600-1.18%
Post-market: 30.170.00000.00%16:20 EDT
Volume:100.00K
Turnover:3.01M
Market Cap:358.68M
PE:20.66
High:30.82
Open:30.39
Low:29.49
Close:30.53
52wk High:39.92
52wk Low:18.35
Shares:11.89M
Float Shares:9.59M
Volume Ratio:0.93
T/O Rate:1.04%
Dividend:- -
Dividend Rate:- -
EPS(TTM):1.46
EPS(LYR):1.46
ROE:34.12%
ROA:2.88%
PB:4.28
PE(LYR):20.66

Loading ...

XOMA Royalty Is Maintained at Outperform by Leerink Partners

Dow Jones
·
Dec 12, 2025

XOMA Royalty Corp (Pre-Reincorporation) : Leerink Partners Cuts Target Price to $45 From $58

THOMSON REUTERS
·
Dec 11, 2025

XOMA Royalty Initiated at Buy by LUCID CAPITAL MARKETS

Dow Jones
·
Dec 10, 2025

XOMA Royalty Completes Acquisition of Mural Oncology

MT Newswires Live
·
Dec 05, 2025

BRIEF-Xoma Royalty Announces Closing Of Transaction To Acquire Mural Oncology PLC

Reuters
·
Dec 05, 2025

XOMA Royalty Announces Closing of Transaction to Acquire Mural Oncology Plc

THOMSON REUTERS
·
Dec 05, 2025

Mural Oncology Announces Final Cash Consideration Payable on Closing of Acquisition by XOMA Royalty

THOMSON REUTERS
·
Nov 26, 2025

Mural Oncology Plc - Total Cash Consideration of $2.035 per Share

THOMSON REUTERS
·
Nov 26, 2025

BRIEF-Xoma Royalty Announces Closing Of Transactions To Acquire Lava Therapeutics N.V.

Reuters
·
Nov 21, 2025

XOMA Royalty Closes Acquisition of LAVA Therapeutics

Reuters
·
Nov 21, 2025

XOMA Royalty Announces Closing of Transactions to Acquire LAVA Therapeutics N.v.

THOMSON REUTERS
·
Nov 21, 2025

UPDATE: XOMA Q3 Adj. EPS $(0.29) Misses $(0.04) Estimate, Adj. EPS Excludes Gains On Acquisitions Of $0.99 Per Share

Benzinga
·
Nov 13, 2025

Analysts Conflicted on These Healthcare Names: Alkermes (ALKS), Xoma (XOMA) and Novavax (NVAX)

TIPRANKS
·
Nov 13, 2025

XOMA Q3 EPS $0.70 May Not Be Comparable To $(0.04) Estimate, Sales $9.351M Miss $11.467M Estimate

Benzinga
·
Nov 12, 2025

BRIEF-XOMA Q3 EPS USD 0.7

Reuters
·
Nov 12, 2025

XOMA Royalty reports Q3 revenue of $9.4 million and year-to-date revenue of $38.4 million

Reuters
·
Nov 12, 2025

XOMA Q3 Operating Expenses USD 10.681 Million

THOMSON REUTERS
·
Nov 12, 2025

Press Release: XOMA Royalty Reports Third Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements

Dow Jones
·
Nov 12, 2025

Press Release: Mural Oncology Announces that Mural Shareholders Approve the Proposed Acquisition by XRA 5 Corp., a Wholly Owned Subsidiary of XOMA Royalty

Dow Jones
·
Oct 25, 2025

XOMA Royalty Lowers Cash Offer for Lava Therapeutics, Extends Tender Deadline

MT Newswires Live
·
Oct 18, 2025